drugset / Trial / NCT01365936
hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF
RandomizedParallel-groupOpen-labelTreatment
Summary
There have been some controversies regarding the use of preparations with LH activity in patients with polycystic ovary syndrome (PCOS) who have high endogenous LH activity. In this research we aimed to compare urinary menotrophin versus recombinant FSH (rFSH) with respect to the prevention of OHSS
Timeline
- Start
- 2008-01
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gonal-f | Protein / enzyme biologic | 150 iu | — |
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | 150 iu | — |